CareMax (CMAX) Stock Forecast, Price Target & Predictions
CMAX Stock Forecast
CareMax stock forecast is as follows: an average price target of $2.60 (represents a 18.72% upside from CMAX’s last price of $2.19) and a rating consensus of 'Hold', based on 2 wall street analysts offering a 1-year stock forecast.
CMAX Price Target
The average price target for CareMax (CMAX) is $2.60 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $2.20. This represents a potential 18.72% upside from CMAX's last price of $2.19.
CMAX Analyst Ratings
According to 2 Wall Street analysts, CareMax's rating consensus is 'Hold'. The analyst rating breakdown for CMAX stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 2 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
CareMax Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 14, 2024 | AJ Rice | UBS | $2.20 | $2.15 | 2.33% | 0.46% |
| Apr 12, 2024 | Jack Slevin | Jefferies | $3.00 | $2.88 | 4.17% | 36.99% |
| Apr 01, 2024 | AJ Rice | UBS | $6.40 | $4.82 | 32.78% | 192.24% |
| Jan 06, 2023 | - | UBS | $6.00 | $3.61 | 66.20% | 173.97% |
The latest CareMax stock forecast, released on Jul 14, 2024 by AJ Rice from UBS, set a price target of $2.20, which represents a 2.33% increase from the stock price at the time of the forecast ($2.15), and a 0.46% increase from CMAX last price ($2.19).
CareMax Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $2.20 | $3.87 |
| Last Closing Price | $2.19 | $2.19 | $2.19 |
| Upside/Downside | -100.00% | 0.46% | 76.71% |
In the current month, the average price target of CareMax stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CareMax's last price of $2.19. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 14, 2024 | UBS | Neutral | Neutral | Hold |
| Apr 12, 2024 | Jefferies | Hold | Hold | Hold |
| Apr 01, 2024 | UBS | Neutral | Neutral | Hold |
| Jan 06, 2023 | UBS | Buy | Buy | Hold |
CareMax's last stock rating was published by UBS on Jul 14, 2024. The company gave CMAX a "Neutral" rating, the same as its previous rate.
CareMax Financial Forecast
CareMax Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $151.84M | $201.84M | $224.44M | $172.98M | $164.26M | $157.67M | - | $136.92M | $118.31M | $104.62M | $44.92M |
| Avg Forecast | $331.71M | $334.80M | $372.20M | $344.27M | $275.57M | $277.90M | $296.26M | $252.25M | $189.45M | $192.31M | $221.40M | $197.24M | $189.69M | $194.45M | $184.41M | $175.97M | $149.70M | $141.05M | $136.21M | $130.06M | $118.36M | $108.30M | $114.54M |
| High Forecast | $371.79M | $375.24M | $417.16M | $385.86M | $308.87M | $311.47M | $332.05M | $282.73M | $212.34M | $196.42M | $248.14M | $221.07M | $189.78M | $217.94M | $206.69M | $197.23M | $167.78M | $158.09M | $136.21M | $135.23M | $123.08M | $112.62M | $119.10M |
| Low Forecast | $291.64M | $294.35M | $327.23M | $302.68M | $242.28M | $244.33M | $260.47M | $221.78M | $166.57M | $188.20M | $194.65M | $173.41M | $189.60M | $170.96M | $162.13M | $154.71M | $131.61M | $124.01M | $136.21M | $120.94M | $110.07M | $100.72M | $106.51M |
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 2 | 3 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.80% | 1.04% | 1.22% | 0.98% | 1.10% | 1.12% | - | 1.05% | 1.00% | 0.97% | 0.39% |
CareMax's average Quarter revenue forecast for Mar 24 based on 1 analysts is $197.24M, with a low forecast of $173.41M, and a high forecast of $221.07M. CMAX's average Quarter revenue forecast represents a 29.90% increase compared to the company's last Quarter revenue of $151.84M (Dec 23).
CareMax EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 2 | 3 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-476.14M | $-110.47M | $-38.92M | $-4.09M | $1.53M | $-3.40M | - | $-6.03M | $10.38M | $3.62M | $-6.71M |
| Avg Forecast | $-1.47M | $-1.49M | $-1.65M | $-1.53M | $-1.22M | $-1.23M | $-1.32M | $-1.12M | $-840.96K | $-853.63K | $-982.74K | $-875.51K | $-842.02K | $-863.14K | $-818.55K | $-781.11K | $-664.48K | $5.83M | $-604.60K | $-66.33M | $-525.39K | $5.30M | $-23.97M |
| High Forecast | $-1.29M | $-1.31M | $-1.45M | $-1.34M | $-1.08M | $-1.08M | $-1.16M | $-984.43K | $-739.36K | $-835.38K | $-864.01K | $-769.74K | $-841.59K | $-758.86K | $-719.66K | $-686.74K | $-584.21K | $6.99M | $-604.60K | $-53.06M | $-488.57K | $6.35M | $-19.17M |
| Low Forecast | $-1.65M | $-1.67M | $-1.85M | $-1.71M | $-1.37M | $-1.38M | $-1.47M | $-1.25M | $-942.55K | $-871.87K | $-1.10M | $-981.29K | $-842.42K | $-967.42K | $-917.45K | $-875.48K | $-744.76K | $4.66M | $-604.60K | $-79.59M | $-546.32K | $4.24M | $-28.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 565.47% | 127.98% | 47.55% | 5.24% | -2.30% | -0.58% | - | 0.09% | -19.75% | 0.68% | 0.28% |
1 analysts predict CMAX's average Quarter EBITDA for Mar 23 to be $-781.11K, with a high of $-686.74K and a low of $-875.48K. This is -151.19% lower than CareMax's previous annual EBITDA (Dec 22) of $1.53M.
CareMax Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 2 | 3 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-465.77M | $-103.12M | $-32.38M | $-82.08M | $10.43M | $-22.05M | - | $-16.80M | $2.24M | $-2.85M | $-7.36M |
| Avg Forecast | $-3.57M | $-5.03M | $-6.75M | $-7.79M | $-16.96M | $-19.40M | $-21.47M | $-20.22M | $-28.69M | $-31.42M | $-31.44M | $-31.46M | $-18.00M | $-12.50M | $-9.66M | $-14.10M | $-7.47M | $-4.59M | $-6.78M | $-113.38M | $-7.65M | $-4.17M | $-29.82M |
| High Forecast | $-3.01M | $-4.24M | $-5.69M | $-6.57M | $-14.29M | $-16.35M | $-18.10M | $-17.04M | $-24.18M | $-23.71M | $-26.51M | $-26.52M | $-15.17M | $-10.54M | $-8.14M | $-11.88M | $-6.30M | $-3.67M | $-6.78M | $-90.70M | $-6.95M | $-3.34M | $-23.86M |
| Low Forecast | $-4.13M | $-5.82M | $-7.81M | $-9.02M | $-19.62M | $-22.45M | $-24.84M | $-23.39M | $-33.19M | $-39.13M | $-36.38M | $-36.40M | $-20.83M | $-14.46M | $-11.17M | $-16.31M | $-8.64M | $-5.51M | $-6.78M | $-136.06M | $-8.05M | $-5.01M | $-35.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 25.87% | 8.25% | 3.35% | 5.82% | -1.40% | 4.80% | - | 0.15% | -0.29% | 0.68% | 0.25% |
CareMax's average Quarter net income forecast for Mar 23 is $-14.10M, with a range of $-16.31M to $-11.88M. CMAX's average Quarter net income forecast represents a -235.11% decrease compared to the company's last Quarter net income of $10.43M (Dec 22).
CareMax SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 2 | 3 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $20.34M | $22.78M | $24.12M | $27.71M | $20.90M | $24.04M | - | $22.28M | $18.93M | $14.86M | $9.66M |
| Avg Forecast | $107.24M | $108.24M | $120.33M | $111.30M | $89.09M | $89.84M | $95.78M | $81.55M | $61.25M | $62.17M | $71.58M | $63.77M | $61.33M | $62.86M | $59.62M | $56.89M | $48.40M | $23.91M | $44.03M | $42.05M | $38.27M | $21.74M | $39.11M |
| High Forecast | $120.20M | $121.31M | $134.87M | $124.75M | $99.85M | $100.70M | $107.35M | $91.40M | $68.65M | $63.50M | $80.22M | $71.47M | $61.36M | $70.46M | $66.82M | $63.76M | $54.24M | $28.69M | $44.03M | $43.72M | $39.79M | $26.08M | $46.93M |
| Low Forecast | $94.28M | $95.16M | $105.79M | $97.85M | $78.33M | $78.99M | $84.21M | $71.70M | $53.85M | $60.84M | $62.93M | $56.06M | $61.29M | $55.27M | $52.41M | $50.02M | $42.55M | $19.13M | $44.03M | $39.10M | $35.58M | $17.39M | $31.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.33% | 0.36% | 0.40% | 0.49% | 0.43% | 1.01% | - | 0.53% | 0.49% | 0.68% | 0.25% |
CareMax's average Quarter SG&A projection for Mar 24 is $63.77M, based on 1 Wall Street analysts, with a range of $56.06M to $71.47M. The forecast indicates a 213.45% rise compared to CMAX last annual SG&A of $20.34M (Dec 23).
CareMax EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 2 | 3 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.12 | $-0.92 | $-0.29 | $-0.74 | $0.10 | $-0.25 | - | $-0.19 | $0.03 | $-0.03 | $-0.26 |
| Avg Forecast | $-0.94 | $-1.32 | $-1.77 | $-2.05 | $-4.45 | $-5.10 | $-5.64 | $-5.31 | $-7.53 | $-8.25 | $-8.26 | $-8.26 | $-4.73 | $-3.28 | $-2.54 | $-3.70 | $-1.96 | $-1.91 | $-1.79 | $-0.42 | $-2.05 | $-2.48 | $-1.20 |
| High Forecast | $-0.79 | $-1.11 | $-1.50 | $-1.73 | $-3.75 | $-4.30 | $-4.75 | $-4.48 | $-6.35 | $-6.23 | $-6.96 | $-6.97 | $-3.99 | $-2.77 | $-2.14 | $-3.12 | $-1.65 | $-1.61 | $-1.79 | $-0.38 | $-1.86 | $-2.25 | $-1.09 |
| Low Forecast | $-1.09 | $-1.53 | $-2.05 | $-2.37 | $-5.15 | $-5.90 | $-6.52 | $-6.14 | $-8.72 | $-10.28 | $-9.56 | $-9.56 | $-5.47 | $-3.80 | $-2.93 | $-4.28 | $-2.27 | $-2.21 | $-1.79 | $-0.44 | $-2.15 | $-2.60 | $-1.26 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.03% | 0.28% | 0.11% | 0.20% | -0.05% | 0.13% | - | 0.46% | -0.01% | 0.01% | 0.22% |
According to 1 Wall Street analysts, CareMax's projected average Quarter EPS for Mar 23 is $-3.70, with a low estimate of $-4.28 and a high estimate of $-3.12. This represents a -3802.41% decrease compared to CMAX previous annual EPS of $0.10 (Dec 22).
CareMax Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HCAT | Health Catalyst | $8.70 | $29.25 | 236.21% | Buy |
| FORA | Forian | $2.22 | $4.50 | 102.70% | Buy |
| CERT | Certara | $10.83 | $21.75 | 100.83% | Hold |
| PRVA | Privia Health Group | $18.80 | $33.82 | 79.89% | Buy |
| EVH | Evolent Health | $30.54 | $44.00 | 44.07% | Buy |
| HQY | HealthEquity | $78.80 | $97.00 | 23.10% | Buy |
| CMAX | CareMax | $2.19 | $2.60 | 18.72% | Hold |
CMAX Forecast FAQ
Is CareMax a good buy?
No, according to 2 Wall Street analysts, CareMax (CMAX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of CMAX's total ratings.
What is CMAX's price target?
CareMax (CMAX) average price target is $2.6 with a range of $2.2 to $3, implying a 18.72% from its last price of $2.19. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will CareMax stock go up soon?
According to Wall Street analysts' prediction for CMAX stock, the company can go up by 18.72% (from the last price of $2.19 to the average price target of $2.6), up by 36.99% based on the highest stock price target, and up by 0.46% based on the lowest stock price target.
Can CareMax stock reach $3?
CMAX's average twelve months analyst stock price target of $2.6 does not support the claim that CareMax can reach $3 in the near future.
What are CareMax's analysts' financial forecasts?
CareMax's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.1B (high $1.24B, low $968.85M), average EBITDA is $-4.892M (high $-4.301M, low $-5.482M), average net income is $-78.047M (high $-65.789M, low $-90.304M), average SG&A $356.26M (high $399.3M, low $313.22M), and average EPS is $-20.498 (high $-17.279, low $-23.717). CMAX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.38B (high $1.55B, low $1.22B), average EBITDA is $-6.139M (high $-5.397M, low $-6.88M), average net income is $-23.154M (high $-19.517M, low $-26.79M), average SG&A $447.1M (high $501.12M, low $393.09M), and average EPS is $-6.081 (high $-5.126, low $-7.036).
Did the CMAX's actual financial results beat the analysts' financial forecasts?
Based on CareMax's last annual report (Dec 2023), the company's revenue was $751.1M, beating the average analysts forecast of $744.52M by 0.88%. Apple's EBITDA was $-711M, beating the average prediction of $-3.305M by 21409.68%. The company's net income was $-683M, beating the average estimation of $-54.254M by 1159.53%. Apple's SG&A was $94.96M, missing the average forecast of $240.7M by -60.55%. Lastly, the company's EPS was $-0.18, missing the average prediction of $-14.249 by -98.74%. In terms of the last quarterly report (Dec 2023), CareMax's revenue was $151.84M, missing the average analysts' forecast of $189.69M by -19.96%. The company's EBITDA was $-476M, beating the average prediction of $-842K by 56446.78%. CareMax's net income was $-466M, beating the average estimation of $-18.001M by 2487.49%. The company's SG&A was $20.34M, missing the average forecast of $61.33M by -66.83%. Lastly, the company's EPS was $-0.12, missing the average prediction of $-4.728 by -97.46%